Hyperglycemia is a topic frequently discussed in hospitals today. It is not a defining characteristic of diabetes, but is a hefty threat to the body if not addressed in a timely manner. When left untreated, hyperglycemia can cause long-term complications of diabetes such as: eye damage, heart attack, kidney damage, nerve damage, and stroke.

Healthcare puts a strong emphasis on reducing hyperglycemia and rightfully so. However, with the stress on hyperglycemia, let’s not overlook the severity of dosing insulin to reach the other end of the spectrum: hypoglycemia.

Hypoglycemia is one of the most common adverse effects of lowering blood glucose levels in patients with diabetes. It is not only imperative to have an individualized approach to treatment, but also to include the recommended dose essential for those at risk for hypoglycemia.

With EndoTool, a glucose management system, 99.4% of patients achieve control, and blood glucose levels remain within target range as often as 97.25% of the time after control is achieved. The unrivaled performance helps ensure institutions avoid costly readmissions, hospital-acquired infections, and other Hospital Acquired Conditions that are the result of poor glucose control.

The EndoTool platform is built on propriety and patent pending technology, with algorithms categorized in three main functions: SafeStart, SafeDose, and SafeControl. This dosing recommendation platform maintains control after bringing the patient’s insulin levels down, avoiding hypoglycemia. While it’s imperative to focus on treating hyperglycemia, let’s not overlook the risks of hypoglycemia.